Annual report
4360.TEDINET S100VYLQ
Period2024-04-01 → 2025-03-31
Filed2025-06-25
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 121
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥9.3bn | 2024-04-01 → 2025-03-31 | Cons. | Net sales |
| Revenue | ¥9.7bn | 2023-04-01 → 2024-03-31 | Cons. | Net sales |
| Revenue | ¥11.9bn | 2022-04-01 → 2023-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥10.7bn | 2021-04-01 → 2022-03-31d | Cons. | Net sales (5-year summary) |
| Operating income | −¥342m | 2024-04-01 → 2025-03-31 | Cons. | Operating income |
| Operating income | −¥105m | 2023-04-01 → 2024-03-31 | Cons. | Operating income |
| Ordinary income | −¥275m | 2024-04-01 → 2025-03-31 | Cons. | Ordinary income |
| Ordinary income | −¥10m | 2023-04-01 → 2024-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥1.2bn | 2022-04-01 → 2023-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥881m | 2021-04-01 → 2022-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | −¥794m | 2024-04-01 → 2025-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥80m | 2023-04-01 → 2024-03-31 | Cons. | Income before income taxes |
| Net income (owners) | −¥895m | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥82m | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥821m | 2022-04-01 → 2023-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥712m | 2021-04-01 → 2022-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | −¥895m | 2024-04-01 → 2025-03-31 | Cons. | Profit loss |
| Net income | ¥83m | 2023-04-01 → 2024-03-31 | Cons. | Profit loss |
| Total assets | ¥12.6bn | at 2025-03-31 | Cons. | Assets |
| Total assets | ¥14.1bn | at 2024-03-31 | Cons. | Assets |
| Total assets | ¥15.0bn | at 2023-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥13.6bn | at 2022-03-31d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥2.3bn | at 2025-03-31 | Cons. | Liabilities |
| Total liabilities | ¥2.8bn | at 2024-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥10.3bn | at 2025-03-31 | Cons. | Net assets |
| Net assets / equity | ¥11.2bn | at 2024-03-31 | Cons. | Net assets |
| Net assets / equity | ¥11.0bn | at 2023-03-31d | Cons. | Net assets |
| Net assets / equity | ¥10.3bn | at 2022-03-31d | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥2.8bn | at 2025-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥3.3bn | at 2024-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥2.8bn | at 2025-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥3.3bn | at 2024-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥3.7bn | at 2023-03-31d | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥2.0bn | at 2022-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥108m | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | −¥118m | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥1.6bn | 2022-04-01 → 2023-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥714m | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥489m | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥231m | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | ¥199m | 2022-04-01 → 2023-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥422m | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥126m | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥75m | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥125m | 2022-04-01 → 2023-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥200m | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥-110.77 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥10.3 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥103.26 | 2022-04-01 → 2023-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥90.52 | 2021-04-01 → 2022-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| Net assets per share | ¥1,271.5 | at 2025-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,399.56 | at 2024-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,384.71 | at 2023-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,300.81 | at 2022-03-31d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 81.5% | at 2025-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 79.8% | at 2024-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 73.5% | at 2023-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 75.8% | at 2022-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 0.7% | 2023-04-01 → 2024-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 7.4% | 2022-04-01 → 2023-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 6.9% | 2021-04-01 → 2022-03-31d | Cons. | Rate of return on equity (5-year summary) |
| Employees | 211 | at 2025-03-31 | Cons. | Number of employees |
| Employees | 220 | at 2024-03-31 | Cons. | Number of employees |
| Employees | 236 | at 2023-03-31d | Cons. | Number of employees |
| Employees | 241 | at 2022-03-31d | Cons. | Number of employees |
| Revenue | ¥547m | 2024-04-01 → 2025-03-31 | Standalone | Operating revenue1 |
| Revenue | ¥541m | 2023-04-01 → 2024-03-31 | Standalone | Operating revenue1 |
| Revenue | ¥672m | 2022-04-01 → 2023-03-31d | Standalone | Operating revenue1 (5-year summary) |
| Revenue | ¥317m | 2021-04-01 → 2022-03-31d | Standalone | Operating revenue1 (5-year summary) |
| Operating income | ¥100m | 2024-04-01 → 2025-03-31 | Standalone | Operating income |
| Operating income | ¥91m | 2023-04-01 → 2024-03-31 | Standalone | Operating income |
| Ordinary income | ¥159m | 2024-04-01 → 2025-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥517m | 2023-04-01 → 2024-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥760m | 2022-04-01 → 2023-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥188m | 2021-04-01 → 2022-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥159m | 2024-04-01 → 2025-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥593m | 2023-04-01 → 2024-03-31 | Standalone | Income before income taxes |
| Net income | ¥124m | 2024-04-01 → 2025-03-31 | Standalone | Profit loss |
| Net income | ¥534m | 2023-04-01 → 2024-03-31 | Standalone | Profit loss |
| Net income | ¥662m | 2022-04-01 → 2023-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥174m | 2021-04-01 → 2022-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥12.1bn | at 2025-03-31 | Standalone | Assets |
| Total assets | ¥11.9bn | at 2024-03-31 | Standalone | Assets |
| Total assets | ¥11.2bn | at 2023-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥10.6bn | at 2022-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥234m | at 2025-03-31 | Standalone | Liabilities |
| Total liabilities | ¥175m | at 2024-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥11.8bn | at 2025-03-31 | Standalone | Net assets |
| Net assets / equity | ¥11.7bn | at 2024-03-31 | Standalone | Net assets |
| Net assets / equity | ¥11.1bn | at 2023-03-31d | Standalone | Net assets |
| Net assets / equity | ¥10.5bn | at 2022-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥2.1bn | at 2025-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥2.0bn | at 2024-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥15.41 | 2024-04-01 → 2025-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥66.73 | 2023-04-01 → 2024-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥83.29 | 2022-04-01 → 2023-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥22.05 | 2021-04-01 → 2022-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| Dividend per share | ¥12.5 | 2024-04-01 → 2025-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥15 | 2023-04-01 → 2024-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥15 | 2022-04-01 → 2023-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥7.5 | 2021-04-01 → 2022-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥1,458.45 | at 2025-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,460.86 | at 2024-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,388.88 | at 2023-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,324.77 | at 2022-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 98.1% | at 2025-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 98.5% | at 2024-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 98.5% | at 2023-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 99.2% | at 2022-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 1.1% | 2024-04-01 → 2025-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 4.7% | 2023-04-01 → 2024-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 6.1% | 2022-04-01 → 2023-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 1.7% | 2021-04-01 → 2022-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 8,625,000 | at 2025-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 8,625,000 | at 2024-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 8,625,000 | at 2023-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 8,625,000 | at 2022-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 8 | at 2025-03-31 | Standalone | Number of employees |
| Employees | 9 | at 2024-03-31 | Standalone | Number of employees |
| Employees | 8 | at 2023-03-31d | Standalone | Number of employees |
| Employees | 7 | at 2022-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 60
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | capex | 2024-04-01 → 2025-03-31 | ¥87m |
| Reconciling Itemsreconciling | depreciation | 2024-04-01 → 2025-03-31 | ¥121m |
| Reconciling Itemsreconciling | segment assets | at 2025-03-31 | ¥5.7bn |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2025-03-31 | −¥1.1bn |
| Fine Chemical Businessreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥82m |
| Fine Chemical Businessreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥197m |
| Fine Chemical Businessreportable segment | employees | at 2025-03-31 | 75 pure |
| Fine Chemical Businessreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥3.9bn |
| Fine Chemical Businessreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥3.9bn |
| Fine Chemical Businessreportable segment | segment assets | at 2025-03-31 | ¥3.7bn |
| Fine Chemical Businessreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥603m |
| Flame Retardants Businessreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥253m |
| Flame Retardants Businessreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥140m |
| Flame Retardants Businessreportable segment | employees | at 2025-03-31 | 45 pure |
| Flame Retardants Businessreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥4.0bn |
| Flame Retardants Businessreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥4.0bn |
| Flame Retardants Businessreportable segment | segment assets | at 2025-03-31 | ¥2.4bn |
| Flame Retardants Businessreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥72m |
| Health Support Businessreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥24m |
| Health Support Businessreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥21m |
| Health Support Businessreportable segment | employees | at 2025-03-31 | 11 pure |
| Health Support Businessreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥1.4bn |
| Health Support Businessreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥1.4bn |
| Health Support Businessreportable segment | segment assets | at 2025-03-31 | ¥846m |
| Health Support Businessreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥54m |
| —segment total | capex | 2024-04-01 → 2025-03-31 | ¥360m |
| —segment total | depreciation | 2024-04-01 → 2025-03-31 | ¥359m |
| —segment total | employees | at 2025-03-31 | 131 pure |
| —segment total | revenue | 2024-04-01 → 2025-03-31 | ¥9.3bn |
| —segment total | revenue external | 2024-04-01 → 2025-03-31 | ¥9.3bn |
| —segment total | segment assets | at 2025-03-31 | ¥6.9bn |
| —segment total | segment profit | 2024-04-01 → 2025-03-31 | ¥729m |
| Reconciling Itemsreconciling | capex | 2023-04-01 → 2024-03-31 | ¥97m |
| Reconciling Itemsreconciling | depreciation | 2023-04-01 → 2024-03-31 | ¥122m |
| Reconciling Itemsreconciling | segment assets | at 2024-03-31 | ¥6.1bn |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2024-03-31 | −¥1.1bn |
| Fine Chemical Businessreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥127m |
| Fine Chemical Businessreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥194m |
| Fine Chemical Businessreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥3.9bn |
| Fine Chemical Businessreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥3.9bn |
| Fine Chemical Businessreportable segment | segment assets | at 2024-03-31 | ¥4.0bn |
| Fine Chemical Businessreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥615m |
| Flame Retardants Businessreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥58m |
| Flame Retardants Businessreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥128m |
| Flame Retardants Businessreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥4.4bn |
| Flame Retardants Businessreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥4.4bn |
| Flame Retardants Businessreportable segment | segment assets | at 2024-03-31 | ¥3.1bn |
| Flame Retardants Businessreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥350m |
| Health Support Businessreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥13m |
| Health Support Businessreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥18m |
| Health Support Businessreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥1.4bn |
| Health Support Businessreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥1.4bn |
| Health Support Businessreportable segment | segment assets | at 2024-03-31 | ¥890m |
| Health Support Businessreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥62m |
| —segment total | capex | 2023-04-01 → 2024-03-31 | ¥199m |
| —segment total | depreciation | 2023-04-01 → 2024-03-31 | ¥341m |
| —segment total | revenue | 2023-04-01 → 2024-03-31 | ¥9.7bn |
| —segment total | revenue external | 2023-04-01 → 2024-03-31 | ¥9.7bn |
| —segment total | segment assets | at 2024-03-31 | ¥8.0bn |
| —segment total | segment profit | 2023-04-01 → 2024-03-31 | ¥1.0bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,420
| Item | Context | Value | Unit |
|---|---|---|---|
| Price earnings ratio (5-year summary) | Prior3YearDuration_NonConsolidatedMember | 24.0 | |
| Price earnings ratio (5-year summary) | Prior2YearDuration_NonConsolidatedMember | 9.6 | |
| Price earnings ratio (5-year summary) | Prior1YearDuration_NonConsolidatedMember | 9.3 | |
| Price earnings ratio (5-year summary) | CurrentYearDuration_NonConsolidatedMember | 37.6 | |
| Payout ratio (5-year summary) | Prior3YearDuration_NonConsolidatedMember | 0.340 | |
| Payout ratio (5-year summary) | Prior2YearDuration_NonConsolidatedMember | 0.180 | |
| Payout ratio (5-year summary) | Prior1YearDuration_NonConsolidatedMember | 0.225 | |
| Payout ratio (5-year summary) | CurrentYearDuration_NonConsolidatedMember | 0.811 | |
| Number of employees | Prior3YearInstant_NonConsolidatedMember | 7 | |
| Number of employees | Prior2YearInstant_NonConsolidatedMember | 8 | |
| Number of employees | Prior1YearInstant_NonConsolidatedMember | 9 | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember | 8 | |
| Total shareholder return | Prior3YearInstant_NonConsolidatedMember | 1.028 | |
| Total shareholder return | Prior2YearInstant_NonConsolidatedMember | 1.575 | |
| Total shareholder return | Prior1YearInstant_NonConsolidatedMember | 1.257 | |
| Total shareholder return | CurrentYearInstant_NonConsolidatedMember | 1.205 | |
| Total return on share price index | Prior3YearInstant_NonConsolidatedMember | 1.312 | |
| Total return on share price index | Prior2YearInstant_NonConsolidatedMember | 1.388 | |
| Total return on share price index | Prior1YearInstant_NonConsolidatedMember | 1.962 | |
| Total return on share price index | CurrentYearInstant_NonConsolidatedMember | 1.472 | |
| Number of employees | CurrentYearInstant_jpcrp030000-asr_E36769-000FineChemicalBusinessReportableSegmentsMember | 75 | |
| Number of employees | CurrentYearInstant_jpcrp030000-asr_E36769-000FlameRetardantsBusinessReportableSegmentsMember | 45 | |
| Number of employees | CurrentYearInstant_jpcrp030000-asr_E36769-000HealthSupportBusinessReportableSegmentsMember | 11 | |
| Number of employees | CurrentYearInstant_ReportableSegmentsMember | 131 | |
| Number of employees | CurrentYearInstant_CorporateSharedMember | 80 | |
| Number of employees | CurrentYearInstant | 211 | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember | 8 | |
| Average age years information about reporting company information about employees | CurrentYearInstant_NonConsolidatedMember | 38.2 | |
| Average length of service years information about reporting company information about employees | CurrentYearInstant_NonConsolidatedMember | 8.4 | |
| Average annual salary information about reporting company information about employees | CurrentYearInstant_NonConsolidatedMember | 6893386 | JPY |
| Number of employees | CurrentYearInstant_NonConsolidatedMember_CorporateSharedMember | 8 | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember | 8 | |
| Ratio of female employees in managerial positions metrics of consolidated subsidiaries | CurrentYearInstant_Row1Member | 0.050 | |
| All employees ratio of male employees taking childcare leave metrics of consolidated subsidiaries | CurrentYearInstant_Row1Member | 1.000 | |
| Gross scope1 and2 greenhouse gas emissions scope1 and2 greenhouse gas emissions | Prior2YearDuration_ConsolidatedAccountingGroupMember | 9200 | |
| Gross scope1 and2 greenhouse gas emissions scope1 and2 greenhouse gas emissions | Prior1YearDuration_ConsolidatedAccountingGroupMember | 8100 | |
| Gross scope1 and2 greenhouse gas emissions scope1 and2 greenhouse gas emissions | CurrentYearDuration_ConsolidatedAccountingGroupMember | 8000 | |
| Performance description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row1Member | 2 | |
| Performance description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row2Member | 3.25 | |
| Performance description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row3Member | 3 | |
| Research and development expenses research and development activities | CurrentYearDuration | 480000000 | JPY |
| Research and development expenses research and development activities | CurrentYearDuration_jpcrp030000-asr_E36769-000HealthSupportBusinessReportableSegmentsMember | 13000000 | JPY |
| Research and development expenses research and development activities | CurrentYearDuration_jpcrp030000-asr_E36769-000FineChemicalBusinessReportableSegmentsMember | 190000000 | JPY |
| Research and development expenses research and development activities | CurrentYearDuration_jpcrp030000-asr_E36769-000FlameRetardantsBusinessReportableSegmentsMember | 190000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration | 447000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration_jpcrp030000-asr_E36769-000FineChemicalBusinessReportableSegmentsMember | 82000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration_jpcrp030000-asr_E36769-000FlameRetardantsBusinessReportableSegmentsMember | 253000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration_jpcrp030000-asr_E36769-000HealthSupportBusinessReportableSegmentsMember | 24000000 | JPY |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 8625000 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 8625000 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |